In this COVID-19 clinical update, Daniel Griffin summarizes current status of vaccination in the US, discusses a study on convalescent sera from Argentina, use of remdesivir in patients with kidney disease, and provides further considerations on the use of Ct values in patient management.
On this episode, a discussion of why modifying the dose schedule of the mRNA vaccines in the US is not a good idea, evidence that lower Ct values on hospital admission is associated with higher mortality, and dose-dependent response to SARS-CoV-2 infection of ferrets.
In Daniel Griffin’s final clinical report for 2020, he summarizes what we have learned about the clinical management of COVID-19 patients in the past year.
TWiV reviews additional data on the UK variant of SARS-CoV-2, the distinct variant spreading in South Africa, association of afucosylated antiviral IgG with severe COVID-19, approval of AstraZeneca vaccine in the UK, and winners of the pandemic poem contest.
Daniel Griffin provides his weekly clinical report on COVID-19, including his own experience with vaccination, guidelines for vaccine distribution, reasons for under-utilization of monoclonal antibody therapy, and much more.
TWiV reviews the latest data on the UK variant of SARS-CoV-2, including some properties of the variant and why it is being closely studied, development of liver cancer in a participant in a adenovirus-associated virus gene therapy trial, and answers to listener questions.
TWiV explains that COVID-19 is not harmless for young adults, FAA approval for Pfizer mRNA vaccine, lack of justification for the claim of reverse transcription of SARS-CoV-2 RNA and integration into the human genome, and lack of evidence for increased transmission by new variants in the UK.
Daniel Griffin provides his weekly clinical report on COVID-19, including thoughts on the first immunizations with Pfizer mRNA vaccine, the anticipated EUA for the Moderna vaccine, whether the vaccine prevents infection, not just disease, monoclonal antibody therapy, and much more.
On this episode, TWiV makes Bloomberg Business News 2020 Jealousy List, crushing of CDC revealed by insiders, seasonal influenza during the COVID-19 pandemic, FDA briefing documents from Moderna, and three-quarters attack rate of SARS-CoV-2 during an unmitigated epidemic in Brazil.
On this episode, FDA EUA for Pfizer mRNA vaccine, efficacy of AstraZeneca ChAdOx1 COVID-19 vaccine, and an orally administered drug that blocks SARS-CoV-2 transmission in ferrets.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Brianne Barker, Ph.D.
Rich Condit, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.
Kathy Spindler, Ph.D.